Alzheimer's with Psychosis

What is Alzheimer's with Psychosis?

Alzheimer’s is a progressive neurological disorder characterized by cognitive decline, memory loss, and changes in behavior. It is the most common cause of dementia, a condition that impairs memory, thinking, and behavior to the extent that it interferes with daily functioning. In Alzheimer's, abnormal protein deposits build up in the brain, leading to the death of nerve cells and the breakdown of communication between them. This results in the gradual deterioration of cognitive abilities and the development of symptoms such as forgetfulness, confusion, difficulty with language and decision-making, and changes in mood and personality.

Alzheimer's with psychosis refers to the presence of psychotic symptoms in individuals with Alzheimer's disease. Psychosis involves a detachment from reality and can manifest as hallucinations, which are sensory experiences without a corresponding stimulus (such as seeing or hearing things that aren't there), and delusions, which are false beliefs that are firmly held despite evidence to the contrary. Psychotic symptoms may also include paranoia, agitation, and aggression. These symptoms can significantly impact the individual's perception of reality, behavior, and overall quality of life, often adding to the complexity of managing the disease for both patients and caregivers.

Current Clinical Trial

Our clinical trial, titled "Radiant Study," is currently underway with the goal of finding more possible treatment options for people with Alzheimer’s disease psychosis (ADP). About 1,000 people from around the world, including diverse backgrounds in terms of race, ethnicity, age, and gender, will participate in this study. Participants in this clinical trial may receive compensation for their involvement.

Participating in such research efforts not only offers potential therapeutic advantages to individuals with complex conditions such as Alzheimer's with psychosis but also fosters progress in medical science, leading to improved patient care and outcomes.

Who Can Take Part?

To possibly be able to take part, a person must:

Be 55–95 years of age
Live at home, in a nursing home, or in an assisted-living facility
Have probable Alzheimer’s disease with symptoms of psychosis
Have a designated care partner who can attend all study center visits with them.

The study team will explain the possible benefits and risks of taking part.

What Will the Study Involve?

The study will last about 4 months:

Screening: About six weeks with one study center visit
Treatment: About six weeks
- Make up to five (5) study center visits (person in the study and their care partner)
- Take the study medication (a capsule) by mouth one (1) time a day
- Receive one (1) weekly support phone call from the study team to the care partner
Follow-up: After completing the study, a person will either:
1. Enter the follow-up period of about four weeks and will have up to two phone calls
2. Consider joining an open-label extension (OLE) study to look at the effects of the study drug over a longer time.